• Other
  • Exited

Our most advanced product, ospemifene, received FDA approval in February 2013 for the treatment of moderate to severe dyspareunia (painful sexual intercourse), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. It was launched in May 2013 by our partner Shionogi Inc. under the trade name OsphenaTM.

www.quatrx.com